Leukemia Clinical Trial
Official title:
Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation From HLA Matched Sibling Donors For Treatment Of Patients With High Risk Acute Lymphocytic Leukemia In Complete Remission
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Peripheral stem cell transplantation may be able to replace
immune cells that were destroyed by chemotherapy and radiation therapy. Sometimes the
transplanted cells are rejected by the body's normal tissues. Mycophenolate mofetil and
donor white blood cells may prevent this from happening.
PURPOSE: Phase I/II trial to determine the effectiveness of combination chemotherapy and
total-body irradiation followed by peripheral stem cell transplantation in treating patients
who have acute lymphoblastic leukemia.
Status | Completed |
Enrollment | 0 |
Est. completion date | July 2004 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A to 75 Years |
Eligibility |
DISEASE CHARACTERISTICS: - Diagnosis of acute lymphoblastic leukemia (ALL) - Adult patients must meet 1 of the following criteria: - Age 50 to 75 with high-risk ALL in complete remission (CR) (less than 5% blasts by morphology on bone marrow aspirate and absence of peripheral blasts) or ALL in second CR (CR2) or greater - Age 18 to 50 with high-risk ALL in first CR (CR1) and either ineligible for conventional allogeneic transplantation (based on general medical condition) or refused conventional transplantation - High-risk adult ALL in CR1 includes patients meeting 1 or more of the following criteria: - Age 30 and over - Non-T-cell phenotype - Cytogenetic abnormalities including t(9;22), t(4;11), trisomy 8, or monosomy 7 - Failure to achieve CR after 4 weeks of induction chemotherapy - Age 18 to 50 with ALL in CR2 or greater and ineligible for conventional allogeneic transplantation based on general medical condition - Age 18 to 50 with high-risk ALL in CR2 or greater and refused conventional allogeneic transplantation - Pediatric patients must meet 1 of the following criteria: - Under age 18 with high-risk ALL in CR1 and ineligible for conventional allogeneic transplantation based on general medical condition - High-risk pediatric ALL in CR1 includes patients meeting 1 or more of the following criteria: - Cytogenetic abnormalities - t(9;22) with WBC at least 25,000/mm3 at diagnosis - t(4;11) in patients under age 1 or age 10 and over - Hypodiploidy (no more than 45 chromosomes) - Failure to achieve CR after 4 weeks of induction chemotherapy - Persistent peripheral blasts after 1 week of induction chemotherapy - Under age 18 with CR2 or greater and ineligible for conventional allogeneic transplantation based on general medical condition - Age 12 and under allowed if approved by the principle investigator - No active CNS disease - Availability of a sibling donor (excluding an identical twin) - HLA genotypically identical for at least 1 haplotype - HLA-A, -B, -C, -DRB1, and -DQB1 genotypically or phenotypically identical PATIENT CHARACTERISTICS: Age: - See Disease Characteristics - 75 and under Performance status: - Karnofsky 50-100% (adults) - Lansky 40-100% (children) Life expectancy: - Not specified Hematopoietic: - See Disease Characteristics Hepatic: - No fulminant liver failure - No alcoholic hepatitis - No history of bleeding esophageal varices - No grade II or greater hepatic encephalopathy - No hepatic synthetic dysfunction evidenced by prolongation of PT with INR greater than 2.5 - No intractable ascites related to portal hypertension - No bacterial or fungal liver abscess - No chronic viral hepatitis with bilirubin greater than 5 mg/dL - No biliary obstruction with bilirubin greater than 5 mg/dL - No concurrent symptomatic biliary disease Renal: - Not specified Cardiovascular: - Cardiac ejection fraction at least 30% Pulmonary: - No requirement for supplementary continuous oxygen Other: - HIV negative - Not pregnant or nursing - Fertile patients must use effective contraception during and for 1 year after study participation PRIOR CONCURRENT THERAPY: Biologic therapy - No concurrent posttransplantation growth factors during mycophenolate mofetil administration Chemotherapy - See Disease Characteristics Endocrine therapy - Not specified Radiotherapy - Not specified Surgery - Not specified |
Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Germany | Universitaet Leipzig | Leipzig | |
United States | Cancer Institute at Oregon Health and Science University | Portland | Oregon |
United States | Fred Hutchinson Cancer Research Center | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
Fred Hutchinson Cancer Research Center | National Cancer Institute (NCI) |
United States, Germany,
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT00948064 -
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A |